Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency
NCT05193552Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of polyvalent human immunoglobulin in common variable immunodeficiency (CVID), sponsored by University of Alabama at Birmingham. Started Jan 2024; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NCT05193552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193552.